—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...
—A team of researchers in Tokyo recently took on the challenge of attempting to determine whether comprehensive genomic profiling has clinical utility in a large cohort of patients with non-small cell ...
Biomarker testing in non-small cell lung cancer is underutilized, hindering optimal treatment. Streamlined processes and education are vital for improvement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback